Introducing Verily Lightpath

Verily Lightpath Metabolic — Will be a personalized, AI-powered chronic care solution, backed by deep clinical expertise. Supporting members with certain cardiometabolic conditions, such as type 1 diabetes, type 2 diabetes, hypertension, clinically overweight and obesity. To be available for open enrollment January 2026. Learn more.

Verily Onduo

Precision care for managing diabetes and hypertension

Verily Onduo is a virtual care management solution for people living with type 1 or 2 diabetes and hypertension. Plus, we offer a solution for pre-diabetes and weight management support through our partnership with Good Measures®. We connect members with easy-to-use technology and expert health professionals to build personalized journeys to better health.

Our approach

Support for precisely each member

Health isn’t one-size fits all. We approach better health holistically, connecting on diet, lifestyle and stress management with each unique member on their terms to develop healthy habits.
Two people in their kitchen

More than an app

Managing diabetes and chronic care — Anytime, anywhere

  • Intuitive mobile app
  • Dedicated care team
  • In-app specialist care (when clinically indicated) 
  • Self-guided, tailored content 
  • Connected devices
  • And more
Request more info

Partnering with us

True partners for health plans

We support your plan through customer outreach and team support, including training and sales collateral to help sign and retain ASO clients, plus transition them from incumbent solutions.
Contact an expert
Doctor reviewing medical record with patient

How we compare

Program features
Onduo
Leading competitor 1
Leading competitor 2
Doctors† and care team
Coaches and nutritionist
Pharmacist support
Telemedicine clinic with physicians/specialist
Drugs‡
Medication adherence
Medication review and management
Medication optimization
Remote prescribing
Devices
Digital app experience
Digital coaching and reminders
Connected monitors, e.g., BGM and BPM
BGM supplies included
CGM prescribed
Fitbit Inspire 2 and Fitbit Premium access 1
Chart disclaimers
Note: Comparisons based on internal analysis of publicly available information as of 10/23. Actual offerings may vary. †The Onduo app is not intended as a substitute for individuals' primary care physicians' care or guidance. Onduo members must discuss their treatment plan with said providers before making major lifestyle changes. ‡Not intended for use as a medication reminder system. Members should defer to their prescribing physician's instructions and adjust their in-app medication list per wrong notifications.

Evidence-based outcomes

When holistic data analysis meets human-centric care, more people can realize better health outcomes.

A peer-reviewed, 4-month study of Onduo for type 2 diabetes with intermittent CGM use showed significant improvements in glycemic control and comorbidity biomarkers, such as systolic blood pressure, total cholesterol and weight.1

Image: High risk patients had an average 2.4% A1C decrease, and overall participants experienced an average 1.6% A1C decrease. Other significant outcomes (all averages) include a 4.4 mmHg reduction in systolic blood pressure (avg.), a 16.6 mg/dL decrease in total cholesterol and 9 pound weight loss.1** Note: Weight loss results are not guaranteed. Individual weight loss outcomes, amount and time duration will vary.

Contact an expert
-0

percent A1C decrease (overall avg.)1

-0

percent A1C decrease (avg., high-risk)1

-0

mmHg, systolic blood pressure (avg.) decrease1

-0

mg/dL total cholesterol (avg.) decrease1

-0

lbs weight loss (avg.)1**

Building personalized paths to better health

Steve Aubrey, Onduo Member*

Hear Steve’s testimony

More on Onduo virtual care management

One-pager: Comparison chart of Onduo support versus leading competitors Oct ‘23

Download

Research insights: Outcomes from peer-reviewed study on Onduo for T2D with CGM use

Download
Source(s) and page disclaimers

1. Majithia AR, Kusiak CM, Improved Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor Driven Virtual Diabetes Clinic: A Prospective J Med Internet Res. 2020;22(8):e21778. doi:10.2196/21778 n=55; 60 days intermittent CGM wear,*n=43, https://PubMed.ncbi.nlm.nih.gov/32856597/; Systolic blood pressure decrease = average of all participants, Total cholesterol = average of all participants, Weight loss = average of all participants

* Testimonials are provided by members of the Onduo program via paid sponsorship. The opinions reflect our members' personal experiences with the program. Results may vary and are not guaranteed. Steve Aubrey may or may not be a current Onduo member,  but was at the time of video production.

** Weight loss results are not guaranteed. Individual weight loss outcomes, amount and time duration will vary.

Onduo offers certain care management and coordinated clinical care programs for eligible individuals, as further described within the website. Onduo LLC and a network of affiliated professional entities (collectively, "Onduo") collaborate to offer the services. Onduo services are meant to be used in conjunction with regular in-person clinical services and not intended to replace routine primary care.

Less Steve Aubrey in video, persons pictured are not/were not actual Onduo members. For privacy reasons we have not shown images of real participants, but the imagery represents what actual Onduo members may experience.



Good Measures® is a registered trademark of Good Measures, LLC.